Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8074452 | 1.00 | HTT (0.49) | HTTNCOA1NCOA3NQO2MTNR1A | |
| SCHEMBL8063041 | 0.78 | HTT (0.51) | HTTNCOA1NCOA3NQO2MTNR1A | |
| SCHEMBL7027773 | 0.78 | HTT (0.51) | HTTNCOA1NCOA3NQO2MTNR1A | |
| SCHEMBL5889352 | 0.78 | HTT (0.51) | HTTNCOA1NCOA3NQO2MTNR1A | |
| SCHEMBL1266380 | 0.76 | TAS1R3 (0.51) | HTTNQO2MTNR1AMTNR1BKMT2A | |
| SCHEMBL1266382 | 0.76 | TAS1R3 (0.51) | HTTNQO2MTNR1AMTNR1BKMT2A | |
| SCHEMBL22868047 | 0.75 | LMNA (0.53) | HTTKMT2AMEN1BDKRB1LMNA | |
| SCHEMBL5889343 | 0.75 | MTNR1A (0.45) | HTTNCOA1NCOA3NQO2MTNR1A | |
| SCHEMBL28447485 | 0.74 | DRD5 (0.45) | KMT2AMEN1 | |
| SCHEMBL29741228 | 0.73 | KMT2A (0.50) | HTTKMT2AMEN1BDKRB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041703-B2 | 2-aminotetralines and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-05-09 | — | — | US | disclosed |
| US-6849663-B2 | 2-Aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-02-01 | — | — | US | disclosed |
| US-20030229148-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2003-12-11 | — | — | US | disclosed |
| EP-1017667-B1 | 2-Amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA TAU IND FARMACEUTI (IT) | 2003-11-19 | — | — | EP | disclosed |
| US-20030158266-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2003-08-21 | — | — | US | disclosed |
| US-20020123652-A1 | 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A (IT) | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123652-A1 | 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES | AADAT, IL2, TPMT | HTT 1541/4885NCOA1 4706/4885NCOA3 4632/4885 |
| US-20030229148-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | AADAT, IL2, TPMT | HTT 1280/4885NCOA1 4759/4885NCOA3 4744/4885 |
| US-20030158266-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | AADAT, IL2, TPMT | HTT 1280/4885NCOA1 4759/4885NCOA3 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.